1. A compound of Formula I or a stereoisomer or pharmaceutically acceptable salt thereof: wherein: X, Y, X′, Y′, X″, and Y″ are independently selected from: H, C 1-6 alkyl, halogen, CF 3 , O—C 1-6 alkyl, NO 2 , NR 2 , O(CH 2 ) n CO 2 R, O(CH 2 ) n CN, OCH 2 CH═CHCO 2 R, CH 2 O(CH 2 ) n CO 2 R, CH 2 OCH 2 CH═CHCO 2 R, O(CH 2 ) n PO(OR) 2 , CH 2 O(CH 2 ) n PO(OR) 2 , NR a (CH 2 ) n CO 2 R, NR a (CH 2 ) n PO(OR) 2 , NR a CH 2 CH═CHCO 2 R, NR a SO 2 R, NR a CO(CH 2 ) n CO 2 R, NR a CO(CH 2 ) n CONR a 2 , O(CH 2 ) n C 6 H 4 CO 2 R, O(CH 2 ) n C 6 H 4 (CH 2 ) n CO 2 R, CH 2 O(CH 2 ) n C 6 H 4 CO 2 R, O(CH 2 ) n C 6 H 4 CONR a 2 , O(CH 2 ) n C 6 H 4 (CH 2 ) n CONR 2 , O(CH 2 ) n C 6 H 4 -tetrazole, CH 2 O(CH 2 ) n C 6 H 4 CONR a 2 , CH 2 O(CH 2 ) n C 6 H 4 -tetrazole, O(CH 2 ) n C 6 H 4 (CH 2 ) n -tetrazole, NR a (CH 2 ) n C 6 H 4 CO 2 R, CH 2 NR a (CH 2 ) n C 6 H 4 CO 2 R, NR a (CH 2 ) n C 6 H 4 (CH 2 ) n CO 2 R, NR a (CH 2 ) n C 6 H 4 CONR a 2 , CH 2 NR a (CH 2 ) n C 6 H 4 CONR a 2 , NR a (CH 2 ) n C 6 H 4 (CH 2 ) n CONR a 2 , NR a (CH 2 ) n C 6 H 4 -tetrazole, CH 2 NR a (CH 2 ) n C 6 H 4 -tetrazole, NR a (CH 2 ) n C 6 H 4 (CH 2 ) n -tetrazole, CONHOH, C(NH)NR a 2 , (CH 2 ) n C(NH)NR a 2 , O(CH 2 ) n CONR a 2 , O(CH 2 ) n C(NH)NR a 2 , O(CH 2 ) n C(NOH)NR a 2 , CH 2 O(CH 2 ) n CONR a 2 , NR a (CH 2 ) n CONR a 2 , OCH 2 CH═CHCONR a 2 , CH 2 OCH 2 CH═CHCONR a 2 , NR a CH 2 CH═CHCONR a 2 , (CH 2 ) m -tetrazole, O(CH 2 ) n -tetrazole, O(CH 2 CH 2 O) p R, NR a (CH 2 CH 2 O) p R, and SO 2 NHCH 3 ; Z is selected from: H, C 1-6 alkyl, OH, O—C 1-6 alkyl, O(CH 2 CH 2 O) p R, OC(O)—C 1-6 alkyl, O(CH 2 ) n CO 2 R, OCH 2 CH═CHCO 2 R, O(CH 2 ) n PO(OR) 2 , O(CH 2 ) n CONR a 2 , O(CH 2 ) n C(NH)NH 2 , O(CH 2 ) n C(NOH)NR a 2 , OCH 2 CH═CHCONR a 2 , O(CH 2 ) n -phenyl-(CH 2 ) m CO 2 R, and O(CH 2 ) n -phenyl-(CH 2 ) m -tetrazole; Z′ is selected from H, CO 2 R, and CONR a 2 ; Q is selected from: (CH 2 ) n CHA(CH 2 ) m C(O)NR 2 , (CH 2 ) m CAA″(CH 2 ) m C(O)NR 2 , (CH 2 ) n CHA(CH 2 ) m CO 2 R, (CH 2 ) m CAA″(CH 2 ) m CO 2 R, (CH 2 ) m CHA(CH 2 ) m SO 2 NR 2 , (CH 2 ) m CHA(CH 2 ) m SO 3 R, (CH 2 ) m CHA(CH 2 ) m C(NH)NH 2 , (CH 2 ) m CHA(CH 2 ) m C(NOH)NH 2 , (CH 2 ) m CHA(CH 2 ) m CONHCHA(CH 2 ) m CO 2 R, (CH 2 ) m CAA″(CH 2 ) m CONHCHA(CH 2 ) m CO 2 R, (CH 2 ) m CHA(CH 2 ) m CONHCHA(CH 2 ) m CONHCHA(CH 2 ) m CO 2 R, (CH 2 ) m CHA(CH 2 ) m CONHCHA(CH 2 ) m CONR a 2 , (CH 2 ) m CAA″(CH 2 ) m CONHCHA(CH 2 ) m CONR a 2 , (CH 2 ) m CHA(CH 2 ) m CONHCHA(CH 2 ) m CONHCHA(CH 2 ) m CONR a 2 , C 3 -C 6 -cyclic amino-(CH 2 ) m CO 2 R, C 3 -C 6 -cyclic amino-(CH 2 ) m CONR a 2 , C 3 -C 6 -cycloalkylene-(CH 2 ) m CO 2 R, and C 3 -C 6 -cycloalkylene-(CH 2 ) m CONR 3 2 ; provided that when Q is (CH 2 ) m CAA″(CH 2 ) m C(O)NR 2 or (CH 2 ) m CAA″(CH 2 ) m CO 2 R, then (a) m is other than 0, (b) A is other than H, or (c) both (a) and (b); A is selected from H, C 1-6 alkyl, (CH 2 ) m C 3-6 -cycloalkyl, OH, CH 2 OH, CH(CH 3 )OH, C(CH 3 ) 2 OH, (CH 2 ) n CO 2 R b , (CH 2 ) n C(O)NR b 2 , and (CH 2 ) m -phenyl, wherein the phenyl is substituted with 0-3 groups selected from H, C 1-4 alkyl, halogen, CF 3 , O—C 1-4 alkyl, and NO 2 ; alternatively, Q is CHA(CH 2 ) m C(O)NR 2 or CHA(CH 2 ) m CO 2 R, and (a) A is selected from OH, (CH 2 ) n CO 2 R b , and (CH 2 ) n C(O)NR b 2 ; (b) R is (CH 2 ) m (CHR b ) n (CH 2 ) m OH or CH(CH 2 OH) 2 ; or (c) both (a) and (b); A″ is C 1-6 alkyl; M is C═O or SO 2 ; R is independently selected from H, (CH 2 ) m (CHR b ) n (CH 2 ) m OH, CH(CH 2 OH) 2 , C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl; R a is independently selected from H, (CH 2 ) m (CHR) n (CH 2 ) m OH, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl; R b is independently selected from H, C 1-6 alkyl, C 2-6 alkenyl, and C 2-6 alkynyl; p is selected from 2, 3, 4, 5, 6, 7, 8, 9, 10, 1, and 12; m is selected from 0, 1, 2, 3, and 4; and, n is selected from 1, 2, 3, and 4.